Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pin1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
Pin1 siRNA is an experimental RNA interference (RNAi) modality designed to silence the expression of the PIN1 gene, which encodes the peptidyl-prolyl cis/trans isomerase NIMA-interacting 1 protein. PIN1 is a unique prolyl isomerase that specifically binds and isomerizes phosphorylated serine/threonine–proline motifs, thereby altering the conformation and function of numerous oncogenic and tumor-suppressive proteins. Overexpression of PIN1 is common in various human cancers, including hepatocellular carcinoma, pancreatic cancer, prostate cancer, and glioblastoma, where it promotes cell cycle progression and proliferation. In preclinical research, Pin1 siRNA has been delivered using various systems such as nano-liposomes, GalNAc-conjugated nanoparticles, and thermosensitive hydrogels to inhibit tumor growth and enhance sensitivity to treatments like radiation. It is primarily used as a research tool and has not yet transitioned into a single branded clinical therapeutic asset.
- Other names
- PIN1-silencing siRNAPIN-1-silencing siRNAPIN 1-silencing siRNAsiRNA targeting PIN1
02
Targets
PIN1 (Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1)
Beyond the preview
Go deeper on pin1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pin1 siRNA.